

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1 of 3

Complete if Known

Application Number	
Filing Date	Even Date Herewith
First Named Inventor	David WALLACH
Group Art Unit	1646
Examiner Name	
Attorney Docket Number	WALLACH=17A

 01/04/02
 10/03/00
 01/04/02
U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
JAE	AA	5,359,037		Wallach et al	10-25-1994	
	AB	5,563,039		Goeddel et al	10-08-1996	
	AC	5,674,734		Leder et al	10-07-1997	
	AD	5,712,381		Lin et al	01-27-1998	
	AE	5,830,469		Lynch et al	11-03-1998	
	AF	5,837,817		Aggarwal et al	11-17-1998	
	AG	5,843,675		Lin et al	12-01-1998	
	AH	5,847,099		Lin et al	12-08-1998	
	AI	5,849,501		Lin et al	12-15-1998	
	AJ	5,852,173		Lin et al	12-22-1998	
	AK	5,856,161		Aggarwal et al	01-05-1999	
	AL	5,869,612		Goeddel et al	02-09-1999	
	AM	6,042,826		Caligiuri et al	03-28-2000	

 #2
 JAE
 3/18/02
FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Number			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number	Kind Code ⁵ (if known)				
JAE	AN	EP	0 568 925	A2	Wallach et al	11-10-1993		
	AO	WO	95/31544	A1	Wallach et al	11-23-1995		
	AP	WO	96/12735	A1	Lin et al	05-02-1996		
	AQ	WO	96/30404	A1	Goeddel et al	10-03-1996		
	AR	WO	96/31603	A2	Dixit et al	10-10-1996		
	AS	WO	96/36730	A1	Leder et al	11-21-1996		

Examiner
Signature

Gregory A. Emml

Date
Considered

5/4/2006

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 2

of 3

Complete if Known

Application Number

Filing Date

Even Date Herewith

First Named Inventor

David WALLACH

Group Art Unit

1646

Examiner Name

Attorney Docket Number

WALLACH=17A

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
AL	BE	ITOH et al, "A Novel Protein Domain Required for Apoptosis: Mutational Analysis of Human Fas Antigen", <u>J Biol Chem</u> 268(15):10932-10937 (1993)	
	BF	MARSTERS et al, "Activation of apoptosis by Aop-2 ligand is independent of FADD but blocked by CrmA", <u>Curr Biol</u> 6(6):750-752 (1996)	
	BG	MEDEMA et al, "FLICE is activated by association with the CD95 death-induced signaling complex (DISC)", <u>EMBO J</u> 16(10):2794-2804 (1997)	
	BH	SCHNEIDER et al, "TRAIL receptors 1 (DR4) and 2 (DR5) signal FADD-dependent apoptosis and activate NF- κ B", <u>Immunity</u> 7(6):831-836 (1997)	
	BI	SCREATON et al, "LARD: a new lymphoid-specific death domain containing receptor regulated by alternative pre-mRNA splicing", <u>Proc Natl Acad Sci (USA)</u> 94(9):4615-4619 (1997)	
	BJ	SONG et al, "Aggregation of the Intracellular Domain of the Type 1 Tumor Necrosis Factor Receptor Defined by the Two-hybrid System", <u>J Biol Chem</u> 269(36):22492-22495 (1994)	
	BK	SRINIVASULA et al, "FLAME-1, a novel FADD-like anti-apoptotic molecule that regulates Fas/TNFR1-induced apoptosis", <u>J Biol Chem</u> 272(3):18542-18545 (1997)	
	BL	STANGER et al, "FAP: A Novel Protein Containing a Death Domain That Interacts with Fas/APO-1 (CD95) in Yeast and Causes Cell Death", <u>Cell</u> 81:513-523 (1995)	
	BM	TARTAGLIA et al, "A Novel Domain with the 55 kd TNF Receptor Signals Cell Death", <u>Cell</u> 74:845-853 (1993)	
	BN	VANDEVOORDE et al, "Induced expression of trimerized intracellular domains of the human tumor necrosis factor (TNF) p55 receptor elicits TNF effects", <u>J Cell Biol</u> 137(7):1627-1638 (1997)	
	BO	WANG et al, "Positive and negative regulation of gene expression in eukaryotic cells with an inducible transcriptional regulator", <u>Gene Therapy</u> 4(5):432-441 (1997)	
	BP	YANG et al, "Daxx, a novel Fas-binding protein that activates JNK and apoptosis", <u>Cell</u> 89(7):1067-1076 (19997)	

Examiner
SignatureDate
Considered

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 2

of 3

Complete if Known

Application Number

Filing Date

Even Date Herewith

First Named Inventor

David WALLACH

Group Art Unit

1646

Examiner Name

Attorney Docket Number

WALLACH-17A

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
AT		BOLDIN et al, "Self-association of the "Death Domains" of the p55 Tumor Necrosis Factor (TNF) Receptor and Fas/APO1 Prompts Signaling for TNF and Fas/APO1 Effects", <u>J Biol Chem</u> 270(1):387-391 (1995)	
AU		BOLDIN et al, "A Novel Protein That Interacts with the Death Domain of Fas/APO1 Contains a Sequence Motif Related to the Death Domain", <u>J Biol Chem</u> 270(14):7795-7798 (1995)	
AV		BRAKEBUSCH et al, "Cytoplasmic truncation of the p55 tumor necrosis factor (TNF) receptor abolishes signaling, but not induced shedding of the receptor", <u>EMBO J</u> 11(3):943-950 (1992)	
AW		CHINNAIYAN et al, "FADD, a Novel Death Domain-Containing Protein, Interacts with the Death Domain of Fas and Initiates Apoptosis", <u>Cell</u> 81:505-512 (1995)	
AX		CLEMENT et al, "Fas and Tumor Necrosis Factor Receptor-mediated Cell Death: Similarities and Distinctions", <u>J Exp Med</u> 180:557-567 (1994)	
AW		DELEHANTY et al, "Apoptosis in a Fas-resistant, T-cell receptor-sensitive human leukaemic T-cell clone", <u>Immunology</u> 90(3):383-387 (1997)	
AY		DUAN et al, "RAIDD is a new 'death' adaptor molecule", <u>Nature</u> 385(6611):86-89 (1997)	
AZ		FEINSTEIN et al, "The death domain: a module shared by proteins with diverse cellular functions", <u>TIBS</u> 20:342-344 (1995)	
BA		FREIBERG et al, "Fas signal transduction triggers either proliferation or apoptosis in human fibroblasts", <u>J Invest Dermatol</u> 108(2):215-219 (1997)	
BB		Gagliardini et al, "Prevention of Vertebrate Neuronal Death by the <i>cma</i> Gene", <u>Science</u> 263:826-828 (1994)	
BC		HSU et al, "The TNF Receptor 1-Associated Protein TRADD Signals Cell Death and NF- κ B Activation", <u>CHEMTRACTS-BIOCHEM AND MOL BIOL</u> 5:321-323 (1994)	
BD		HSU et al, "The TNF Receptor 1-Associated Protein TRADD Signals Cell Death and NF- κ B Activation", <u>Cell</u> 81:495-504 (1995)	

Examiner
SignatureDate
Considered

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

WALLACH=17A

Sheet 1 of 8

#2
A. J.
3/18/12

DUPLICATE

5/4/2006

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.